Caveolin-1 as a potential high-risk prostate cancer biomarker

J 2012

Caveolin-1 as a potential high-risk prostate cancer biomarker

GUMULEC, Jaromír, Jiří SOCHOR, Marián HLAVNA, Markéta SZTALMACHOVÁ, Soňa KŘÍŽKOVÁ et. al.

Basic information

Original name

Caveolin-1 as a potential high-risk prostate cancer biomarker

Authors

GUMULEC, Jaromír (203 Czech Republic, belonging to the institution), Jiří SOCHOR (203 Czech Republic), Marián HLAVNA (703 Slovakia, belonging to the institution), Markéta SZTALMACHOVÁ (203 Czech Republic, belonging to the institution), Soňa KŘÍŽKOVÁ (203 Czech Republic), Petr BABULA (203 Czech Republic), Roman HRABEC (203 Czech Republic), Arne ROVNÝ (203 Czech Republic), Vojtěch ADAM (203 Czech Republic), Tomáš ECKSCHLAGER (203 Czech Republic), René KIZEK (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)

Edition

Oncology Reports, 2012, 1021-335X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.297

RIV identification code

RIV/00216224:14110/12:00064830

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.3892/or.2011.1587

UT WoS

000300118700033

Keywords in English

prostate cancer; tumour marker; prognostic marker; immunodetection; electrochemistry; polymerase chain reaction; molecular biology techniques

Abstract

V originále

Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.

Links

NS10200, research and development project

Name: Nádorové markery, jejich stanovení a korelace s karcinomem prostaty

Investor: Ministry of Health of the CR

Citovat

GUMULEC, Jaromír, Jiří SOCHOR, Marián HLAVNA, Markéta SZTALMACHOVÁ, Soňa KŘÍŽKOVÁ, Petr BABULA, Roman HRABEC, Arne ROVNÝ, Vojtěch ADAM, Tomáš ECKSCHLAGER, René KIZEK and Michal MASAŘÍK. Caveolin-1 as a potential high-risk prostate cancer biomarker. Oncology Reports. 2012, vol. 27, No 3, p. 831-841. ISSN 1021-335X. Available from: https://dx.doi.org/10.3892/or.2011.1587.

@article{964785,
   author = {Gumulec, Jaromír and Sochor, Jiří and Hlavna, Marián and Sztalmachová, Markéta and Křížková, Soňa and Babula, Petr and Hrabec, Roman and Rovný, Arne and Adam, Vojtěch and Eckschlager, Tomáš and Kizek, René and Masařík, Michal},
   article_number = {3},
   doi = {http://dx.doi.org/10.3892/or.2011.1587},
   keywords = {prostate cancer; tumour marker; prognostic marker; immunodetection; electrochemistry; polymerase chain reaction; molecular biology techniques},
   language = {eng},
   issn = {1021-335X},
   journal = {Oncology Reports},
   title = {Caveolin-1 as a potential high-risk prostate cancer biomarker},
   volume = {27},
   year = {2012}
}

TY  - JOUR
ID  - 964785
AU  - Gumulec, Jaromír - Sochor, Jiří - Hlavna, Marián - Sztalmachová, Markéta - Křížková, Soňa - Babula, Petr - Hrabec, Roman - Rovný, Arne - Adam, Vojtěch - Eckschlager, Tomáš - Kizek, René - Masařík, Michal
PY  - 2012
TI  - Caveolin-1 as a potential high-risk prostate cancer biomarker
JF  - Oncology Reports
VL  - 27
IS  - 3
SP  - 831-841
EP  - 831-841
SN  - 1021335X
KW  - prostate cancer
KW  - tumour marker
KW  - prognostic marker
KW  - immunodetection
KW  - electrochemistry
KW  - polymerase chain reaction
KW  - molecular biology techniques
N2  - Current diagnostic techniques of prostate cancer cannot efficiently distinguish the latent and low-risk forms from the high-risk significant forms of prostate cancer. Caveolin-1 (Cav-1), except other functions, plays an important role in cell transformation and the process of tumorigenesis. Furthermore, Cav-1 is involved in metastatic processes. It has also been shown that Cav-1 expression is induced under stress conditions, such as oxidative stress. The present study focused on the determination of prognostic markers of aggressive (high-grade) forms of prostate cancer. We determined serum Cav-1 and serum markers of antioxidant activity-glutathione (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum samples (82 prostate cancer patients and 15 controls). We found insignificant differences in Cav-1 between the sera of patients and controls (5.69 in the cancer group vs. 5.42 ng/ml in the control group). However, we found a significant (p<0.004) 2.8-fold elevation of Cav-1 in high tumour stages (TNM T4) compared to lower stages and a significant positive association with histological grading (r=0.29, p=0.028). We also found that in patients with high serum Cav-1 the antioxidant capacity of the body is reduced. These findings indicate that Cav-1 may be an interesting tool for the prediction of disease burden.
ER  -

GUMULEC, Jaromír, Jiří SOCHOR, Marián HLAVNA, Markéta SZTALMACHOVÁ, Soňa KŘÍŽKOVÁ, Petr BABULA, Roman HRABEC, Arne ROVNÝ, Vojtěch ADAM, Tomáš ECKSCHLAGER, René KIZEK and Michal MASAŘÍK. Caveolin-1 as a potential high-risk prostate cancer biomarker. \textit{Oncology Reports}. 2012, vol.~27, No~3, p.~831-841. ISSN~1021-335X. Available from: https://dx.doi.org/10.3892/or.2011.1587.

Detailed Information on Publication Record